Drug-Eluting Stent Trial Goals To Shift From Superiority To Equivalency – FDA
This article was originally published in The Gray Sheet
Executive Summary
Future pivotal trials of drug-eluting stents should include both angiographic and clinical endpoints, and aim to demonstrate equivalency to previously approved drug-eluting stents, FDAers say